Inhibrx Biosciences Hits Day Low of $99.70 Amid Price Pressure

Inhibrx Biosciences, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock price dropping by 8.37%. The stock reached an intraday low of USD 99.70, reflecting a challenging trading session. Over the past week, Inhibrx has seen a decrease of 6.74%, and its performance over the last month has been even more pronounced, with a decline of 11.96%. Despite these short-term setbacks, the company has demonstrated remarkable growth over the past year, boasting a staggering return of 707.97%, significantly outpacing the S&P 500's 27.93% increase during the same period. Financial metrics indicate that while Inhibrx has achieved net sales of USD 1.3 million, representing a remarkable growth rate of 1,200%, it continues to face challenges with a net profit of USD -63.91 million. Additionally, the company's debt-to-equity ratio stands at -1.38, and it currently offers no dividend yield. Promoter confidence appears to be rising, as stakeholders have increased their holdings by 0.81% in the last quarter, now owning 11.85% of the company.